Drug Overdose – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Drug Overdose – Pipeline Review, H1 2017’, provides an overview of the Drug Overdose pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Drug Overdose, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Drug Overdose

– The report reviews pipeline therapeutics for Drug Overdose by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Drug Overdose therapeutics and enlists all their major and minor projects

– The report assesses Drug Overdose therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Drug Overdose

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Drug Overdose

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Drug Overdose pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Fab'entech SA

INSYS Therapeutics Inc

Klaria Pharma Holding AB

Opiant Pharmaceuticals Inc

Ventria Bioscience

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Drug Overdose Overview

Drug Overdose Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Drug Overdose Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Overdose Companies Involved in Therapeutics Development

Fab'entech SA

INSYS Therapeutics Inc

Klaria Pharma Holding AB

Opiant Pharmaceuticals Inc

Ventria Bioscience

Drug Overdose Drug Profiles

FBT-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-00514 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEN-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug Overdose Dormant Projects

Drug Overdose Discontinued Products

Drug Overdose Product Development Milestones

Featured News & Press Releases

Mar 16, 2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose

Mar 15, 2017: Mucodel Pharma Announces Patent Allowance for Mucodel’s Co-Gel Buccal Naloxone (Exonal)

Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents

Feb 28, 2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S.

Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray

Jan 30, 2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas

Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals

Jan 09, 2017: Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN Nasal Spray and Heroin Vaccine Development

Nov 22, 2016: Adapt Pharma Welcomes U.S. Food and Drug Administration Consumer Update Regarding Opioids

Oct 27, 2016: Opiant Pharmaceuticals Announces FDA Orange Book Listing for Narcan Nasal Spray Patent

Oct 06, 2016: FDA Joint Meeting Endorses Commitment to Higher Doses and Broader Access for Naloxone to Help in Fight Against Opioid Overdose

Oct 05, 2016: Adapt Pharma Announces NARCAN coverage with California Medi-Cal Program

Oct 03, 2016: Health Canada Approves Adapt Pharmas Naloxone Hydrochloride Nasal Spray to Treat Opioid Overdose

Sep 20, 2016: Newly Published Study Finds NARCAN Nasal Spray Concentrated Formulation Rapidly Delivers an Effective Naloxone Dose and is Readily Usable by the General Public

Jul 12, 2016: Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN (Naloxone HCl) Nasal Spray - a new Treatment for Opioid Overdose

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Drug Overdose, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Drug Overdose Pipeline by Fab'entech SA, H1 2017

Drug Overdose Pipeline by INSYS Therapeutics Inc, H1 2017

Drug Overdose Pipeline by Klaria Pharma Holding AB, H1 2017

Drug Overdose Pipeline by Opiant Pharmaceuticals Inc, H1 2017

Drug Overdose Pipeline by Ventria Bioscience, H1 2017

Drug Overdose Dormant Projects, H1 2017

Drug Overdose Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Drug Overdose, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports